Evidence map›Paper›PMID 41176592›Full record

ReviewEye and vision (London, England)2025

Discovery and design of photocyclic animal opsins: potential application to gene therapy from non-visual opsin research.

Takahiro Yamashita

Abstract readReview
In one paragraph

Review in Eye and vision (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Takahiro YamashitaDepartment of Biophysics, Graduate School of Science, Kyoto University, Kyoto, 606-8502, Japan. yamashita.takahiro.4z@kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-7956-9288

Funding

Core Research for Evolutional Science and Technology JPMJCR1753Japan Agency for Medical Research and Development 22gm1510007Japan Society for the Promotion of Science 24K09530
6 · The paper itself

Abstract

Opsins are universal photoreceptive proteins in animals. Rhodopsin is the best-studied opsin and functions as a visual sensor in rod cells of human and mouse retinas. Rhodopsin produces an active state upon photoreception, which triggers the signal transduction cascade to evoke a hyperpolarizing response of the cells. This active state is a metastable intermediate and cannot convert back to the dark state by either photoreaction or thermal reaction. Thus, vertebrate rhodopsin is categorized as a mono-stable opsin. Recent accumulation of genomic information in animals has expanded the known repertoires of opsin genes, which are responsible for visual and non-visual photoreceptive functions. The analysis of these opsins revealed that many opsins, including non-visual opsins such as Opn4 and Opn5, form a stable active state upon photoreception and this active state can photo-convert back to the dark state. These opsins have the property of photoreversibility between the dark and active states and thus are categorized as bistable opsins. In addition, we previously identified a different type of non-visual opsin, Opn5L1, whose activity is controlled by a photocyclic reaction. This photocyclic reaction is quite similar to that of channelrhodopsin and is achieved by a special mechanism involving a cysteine residue at position 188 that has not been observed in any other opsins so far. This review would like to focus on the unique photocyclic animal opsin in the context of the diversity of visual and non-visual opsins and also discuss the possibility of designing "artificial photocyclic opsins" from natural opsins for potential application in optogenetic gene therapy.

Identifiers

PMID41176592
PMCPMC12579811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.